# COL1A1

## Overview
The COL1A1 gene encodes the collagen type I alpha 1 chain, a fundamental component of the extracellular matrix, particularly in connective tissues such as skin, bone, and tendons. This gene is responsible for producing one of the two alpha chains that form type I collagen, a fibrillar collagen that provides tensile strength and structural integrity to tissues. The protein encoded by COL1A1 is categorized as a structural protein and undergoes extensive post-translational modifications, including hydroxylation and glycosylation, which are essential for the formation of a stable triple-helix structure. This structure is crucial for the assembly of collagen fibrils, which interact with various cell receptors to influence cell adhesion, signaling, and tissue homeostasis (Devos2023Reviewing). Mutations in the COL1A1 gene are associated with several connective tissue disorders, most notably osteogenesis imperfecta, underscoring its clinical significance (Pollitt2006Mutation).

## Structure
The COL1A1 gene encodes the alpha-1 chain of type I collagen, a crucial component of the extracellular matrix. The primary structure of the COL1A1 protein consists of 1464 amino acids, featuring a repeating Gly-X-Y sequence, where X is often proline and Y is often 4-hydroxyproline (Devos2023Reviewing). This sequence is essential for forming the secondary structure, a triple helix composed of three left-handed polyproline helices that combine into a right-handed triple helix (Devos2023Reviewing).

The tertiary and quaternary structures involve the assembly of three alpha chains into a stable triple helix, typically forming a heterotrimer of two COLα1 (I) chains and one COLα2 (I) chain (Devos2023Reviewing). The N-terminal propeptide contains a von Willebrand factor type C domain, while the C-terminal propeptide includes the Fibrillar collagen C-terminal non-collagenous domain (NC1), also known as COLF, which is essential for maintaining the correct chain combination and orientation (Devos2023Reviewing).

Post-translational modifications are critical for the maturation and function of COL1A1, including hydroxylation of lysyl and prolyl residues, glycosylation of hydroxylysines, and disulfide bond formation. These modifications are vital for collagen's structural integrity and function, such as hydroxylation for fibril formation and hydroxylysyl for cross-linking (Devos2023Reviewing).

## Function
The COL1A1 gene encodes the alpha-1 chain of type I collagen, a critical structural protein in the extracellular matrix of connective tissues such as skin, bone, and tendons. In healthy human cells, the COL1A1 protein is involved in the synthesis and assembly of collagen fibrils, which are essential for providing tensile strength and structural integrity to tissues (Devos2023Reviewing; Li1995Positive). The protein undergoes several post-translational modifications, including hydroxylation and glycosylation, which are crucial for forming a stable triple-helix structure with two COLα1 (I) chains and one COLα2 (I) chain. This structure is stabilized by cross-linking, which is vital for the function of collagen fibrils (Devos2023Reviewing).

The COL1A1 protein interacts with various cell receptors, such as integrins and discoidin domain receptors, playing a role in cell adhesion and signaling pathways. These interactions are important for maintaining tissue homeostasis and responding to mechanical stress (Devos2023Reviewing). The protein is primarily active in the endoplasmic reticulum, where it undergoes modifications before being secreted into the extracellular space, contributing to tissue repair and maintenance (Devos2023Reviewing).

## Clinical Significance
Mutations in the COL1A1 gene are primarily associated with osteogenesis imperfecta (OI), a genetic disorder characterized by brittle bones and a range of clinical phenotypes from mild to lethal. The majority of OI cases are caused by autosomal dominant mutations in COL1A1, with glycine substitutions in the helical domain being common in severe phenotypes, while frameshift and nonsense mutations typically result in milder outcomes (Pollitt2006Mutation). Specific mutations, such as p.Gly257Arg, p.Gly767Ser, and p.Gly821Ser, have been identified as potential mutation hotspots for OI (Zhang2016Clinical). 

In addition to OI, COL1A1 mutations are linked to other conditions, including Ehlers-Danlos syndrome, which affects skin and joint elasticity, and various ocular abnormalities such as blue sclera, thin cornea, and glaucoma (Mauri2016Expanding). Alterations in COL1A1 expression can also contribute to fibrosis and certain cancers. The gene's role in collagen production is crucial, and disruptions can lead to significant structural and functional impairments in connective tissues, highlighting its clinical significance in a range of disorders (Venturi2006Osteogenesis).

## Interactions
The COL1A1 gene encodes the alpha-1 chain of type I collagen, which is involved in various physical interactions with other proteins and nucleic acids. The COLα1 (I) protein, a component of collagen I, interacts with several cell receptors, including integrins, Endo180, Discoidin Domain Receptors (DDR), and Leukocyte-Associated Immunoglobulin-like Receptor (LAIR). These interactions induce diverse downstream signaling pathways. Integrins, particularly the β subunits, are crucial for the transition of reactive astrocytes to scar-forming astrocytes in spinal cord injury models and influence cancer cell migration and invasion (Devos2023Reviewing). Endo180 mediates the uptake and degradation of collagen I, impacting matrix architecture, while DDRs, which are receptor tyrosine kinases, influence fibrillogenesis and ECM remodeling, with implications in cancer cell growth (Devos2023Reviewing). LAIR-1, an immune checkpoint inhibitor, interacts with collagen I, affecting immune responses and potentially contributing to immune evasion in tumors (Devos2023Reviewing).

Additionally, COLα1 (I) is involved in the Wnt-Planar Cell Polarity pathway and interacts with CXCR4 in cancer cell lines, influencing cell migration and signaling pathways (Devos2023Reviewing). These interactions highlight the multifaceted role of COLα1 (I) in cellular processes and disease mechanisms.


## References


[1. (Zhang2016Clinical) Hao Zhang, Hua Yue, Chun Wang, Weiwei Hu, Jiemei Gu, Jinwei He, Wenzhen Fu, Yunqiu Hu, Miao Li, and Zhenlin Zhang. Clinical characteristics and the identification of novel mutations of col1a1 and col1a2 in 61 chinese patients with osteogenesis imperfecta. Molecular Medicine Reports, 15(2):1002–1002, December 2016. URL: http://dx.doi.org/10.3892/mmr.2016.6095, doi:10.3892/mmr.2016.6095. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/mmr.2016.6095)

[2. (Devos2023Reviewing) Hanne Devos, Jerome Zoidakis, Maria G. Roubelakis, Agnieszka Latosinska, and Antonia Vlahou. Reviewing the regulators of col1a1. International Journal of Molecular Sciences, 24(12):10004, June 2023. URL: http://dx.doi.org/10.3390/ijms241210004, doi:10.3390/ijms241210004. This article has 15 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms241210004)

[3. (Li1995Positive) Liye Li, Carol M. Artlett, Sergio A. Jimenez, David J. Hall, and John Varga. Positive regulation of human α1 (i) collagen promoter activity by transcription factor sp1. Gene, 164(2):229–234, October 1995. URL: http://dx.doi.org/10.1016/0378-1119(95)00508-4, doi:10.1016/0378-1119(95)00508-4. This article has 45 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/0378-1119(95)00508-4)

[4. (Mauri2016Expanding) Lucia Mauri, Steffen Uebe, Heinrich Sticht, Urs Vossmerbaeumer, Nicole Weisschuh, Emanuela Manfredini, Edoardo Maselli, Mariacristina Patrosso, Robert N. Weinreb, Silvana Penco, André Reis, and Francesca Pasutto. Expanding the clinical spectrum of col1a1 mutations in different forms of glaucoma. Orphanet Journal of Rare Diseases, August 2016. URL: http://dx.doi.org/10.1186/s13023-016-0495-y, doi:10.1186/s13023-016-0495-y. This article has 30 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s13023-016-0495-y)

[5. (Pollitt2006Mutation) Rebecca Pollitt, Robert McMahon, Janice Nunn, Robert Bamford, Amal Afifi, Nicholas Bishop, and Ann Dalton. Mutation analysis ofcol1a1andcol1a2in patients diagnosed with osteogenesis imperfecta type i-iv. Human Mutation, 27(7):716–716, July 2006. URL: http://dx.doi.org/10.1002/humu.9430, doi:10.1002/humu.9430. This article has 87 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.9430)

[6. (Venturi2006Osteogenesis) G Venturi, E Tedeschi, M Mottes, M Valli, M Camilot, S Viglio, F Antoniazzi, and L Tatò. Osteogenesis imperfecta: clinical, biochemical and molecular findings. Clinical Genetics, 70(2):131–139, July 2006. URL: http://dx.doi.org/10.1111/j.1399-0004.2006.00646.x, doi:10.1111/j.1399-0004.2006.00646.x. This article has 38 citations and is from a peer-reviewed journal.](https://doi.org/10.1111/j.1399-0004.2006.00646.x)